Mieloma Multiple - Mieloma.com

Me gustaria que alguien pueda responder a mi pregunta.

 Deseo saber si una persona q padece del Mieloma Multiple y que a su vez tiene fallas del riñon  yesta en dialisis

podria recibir un transplante de riñon?

Hola!!!
no sé si te valdrá este articulo publicado en SMATBRIEFde hace mes y medio...

Cita  :


      " National Center for Biotechnology Information (NCBI)      
PubMed
                    

1: Contrib Nephrol. 2007;153:182-94.Click here to read  Links
    High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction.

        * Pineda-Roman M,
        * Tricot G.

    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

    Multiple mycloma causes a disproportionate amount of the malignancy-related renal insufficiency. Acute renal insufficiency in myeloma patients can occur due to dehydration, hypercalcemia, side effects of medications (NSAIDs) or tumor lysis syndrome in addition to cast nephropathy, amyloidosis and light chain deposition disease. Patients on hemodialysis have traditionally been excluded from antineoplastic therapy due to fear of side effects and lack of studies addressing benefit. Melphalan is the most effective chemotherapeutic agent in myeloma and its PK (pharmacokinetics) are not adversely affected by impaired renal function. Because of more pronounced toxicity of Melphalan 200 mg/m2 conditioning regimen, Melphalan 140 mg/m2 has become the standard of care. 24% of patients become dialysis-independent at a median of 4 months after autotransplantation. Favorable factors for becoming dialysis independent were duration of dialysis <or=6 months and pretransplant creatinine clearance >10 ml/min. While no good data are available on the use of thalidomide in the presence of renal failure, it is our experience that severe neuropathy, constipation, lethargy and bradycardia are more frequent in patients with creatinine >or=3 mg/dl. It has become apparent that bisphosphanates-zoledronic acid more than pamidronate-cause renal dysfunction. If patients remain dialysis-dependent after autotransplantation, we recommend to delay considering a renal transplant until at least 3 years after the first transplant."

Final de la cita...
Un abrazo!

En parte, Depende el tratamiento a utilizar... por ejemplo a mi madre cuando decidieron darle VELCADE, ya estaba muy invadida, y justo al momento de la primera dosis, le fallo el riñon, El Velcade elimina sus toxinas por via urinaria, por lo tanto no se justificaba la dialisis, mucho menos un trasplante de riñon por su estado general y la baja de plaquetas...Si la droga a utilizar fuera la VAD, que no se elimina por orina, sería diferente.